IDEXX Laboratories (FRA:IX1) Total Equity: €1,346 Mil (As of Mar. 2026)


FRA:IX1 IDEXX Laboratories Inc FRA:IX1
96 GF Score
Price €484.70
GF Value €554.46
Valuation Modestly Undervalued
View Full Analysis

What is IDEXX Laboratories Total Equity?

IDEXX Laboratories FRA:IX1 +1.38% 96 Total Equity is €1,346 Mil as of Mar. 2026. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €554.46 (Modestly Undervalued).

IDEXX Laboratories's total equity for the quarter that ended in Mar. 2026 was €1,346 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

IDEXX Laboratories Total Equity Historical Data

* Premium members only.

The historical data trend for IDEXX Laboratories's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories Total Equity Chart

IDEXX Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 610.64 574.65 1,361.31 1,523.52 1,371.00

IDEXX Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,339.41 1,264.80 1,330.13 1,371.00 1,346.03
FRA:IX1
96GF Score
IDEXX Laboratories Inc FRA:IX1
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDEXX Laboratories Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

IDEXX Laboratories's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=2861.548-1490.551
=1,371

IDEXX Laboratories's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2928.455-1582.426
=1,346

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €1,346 Mil mean?
IDEXX Laboratories (FRA:IX1) has a Total Equity of €1,346 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for IDEXX Laboratories and its competitors.
Is IDEXX Laboratories' Total Equity too high?
IDEXX Laboratories' current Total Equity is €1,346 Mil. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Total Equity compare to A and NTRA?
IDEXX Laboratories' Total Equity of €1,346 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Diagnostics & Research company?
A good Total Equity depends on the Medical Diagnostics & Research industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for IDEXX Laboratories and its competitors. IDEXX Laboratories's current Total Equity is €1,346 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €554.46, compared to a current price of €484.70 — trading 12.6% below its estimated fair value. The current Total Equity is €1,346 Mil. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Total Equity is €1,346 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of €484.70 is trading 12.6% below its estimated GF Value™ of €554.46. GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:IX1:

  • Total Equity: €1,346 Mil
  • GF Value™: €554.46 vs. price of €484.70 (12.6% below fair value)
  • GF Score™: 96/100

No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score

Get the complete analysis for FRA:IX1

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€484.70
Price
€554.46
GF Value